Pancreatic cancer drug promisingKael-GemVax, a cancer vaccine company, said yesterday that results of the third and final phase of clinical testing for GV1001, a pancreatic cancer treatment, were announced by the American Society of Clinical Oncology, an international group of 30,000 physicians and academics interested in cancer trials.
According to the Korea-based biolife engineering company, the results were released in a report by Professor John P. Neoptolemos, head of the division of surgery and oncology at the University of Liverpool. Neoptolemos was in charge of the third-stage of clinical testing of GV1001, called TeloVac.
“The report is an official outcome of an analysis, studying the survivability correlation between GV1001 and eotaxin, a biomarker that moves white blood cells to the infected part of the body,” Kael-GemVax said in a statement. “White blood cells help activate immune cells in the body when it is attacked by viruses.”
Based on the professor’s report on the test result, the 5 percent of pancreatic cancer patients with the highest survival rate who did not receive GV1001 lived for 358 days after diagnosis. These patients had high figures of eotaxin in the body. But the top 5 percent of patients with the highest survival rate that were injected with GV1001 lived 623 days.
“TeloVac is a clinical trial that we have been conducting with the support of the British government since 2007,” said Kim Sang-jae, chief executive of Kael-GemVax. “The latest result of GV1001 is the outcome of the company’s continuous research and development efforts.”
BY LEE EUN-JOO [firstname.lastname@example.org]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)